Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Multicenter, Randomized, Open-label Study of Ifinatamab Deruxtecan (I-DXd), a B7-H3 Antibody Drug Conjugate (ADC), Versus Treatment of Physician's Choice (TPC) in Subjects With Relapsed Small Cell Lung Cancer (SCLC) (IDeate-Lung02)

Trial Profile

A Phase 3, Multicenter, Randomized, Open-label Study of Ifinatamab Deruxtecan (I-DXd), a B7-H3 Antibody Drug Conjugate (ADC), Versus Treatment of Physician's Choice (TPC) in Subjects With Relapsed Small Cell Lung Cancer (SCLC) (IDeate-Lung02)

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 06 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ifinatamab deruxtecan (Primary) ; Amrubicin; Lurbinectedin; Topotecan
  • Indications Small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms IDeate-2; IDeate-Lung02
  • Sponsors Daiichi Sankyo Inc

Most Recent Events

  • 13 Nov 2024 Planned number of patients changed from 468 to 540.
  • 07 Sep 2024 According to Daiichi Sankyo media release, company is looking forward to see additional results from this trial.
  • 01 Aug 2024 According to Daiichi Sankyo media release, company today announced first patient has been dosed in IDeate-Lung02 Phase 3 trial. The initiation of this IDeate-Lung02 trial is based on updated results from a subgroup analysis of the IDeate-PanTumor01.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top